Skip to main content

Table 1 Patient demographics and baseline characteristics (FAS)

From: Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study

  PHN
(n = 89)
HIV-AN
(n = 5)
NBP
(n = 50)
CRNP
(n = 22)
PONP
(n = 198)
Other
(n = 56)
Overall
(n = 420)
Gender, n (%)
 Male 36 (40.4) 5 (100) 17 (34.0) 5 (22.7) 75 (37.9) 29 (51.8) 167 (39.8)
 Female 53 (59.6) 0 33 (66.0) 17 (77.3) 123 (62.1) 27 (48.2) 253 (60.2)
Ethnicity, n (%)
 Caucasian 88 (98.9) 4 (80.0) 49 (98.0) 19 (86.3) 185 (93.4) 55 (98.2) 400 (95.2)
 Asian 0 1 (20.0) 0 0 2 (1.0) 0 3 (0.7)
 Black/African/Caribbean 1 (1.1) 0 1 (2.0) 1 (4.5) 8 (4.0) 1 (1.8) 12 (2.9)
 Mixed/multiple ethnic groups 0 0 0 1 (4.5) 1 (0.5) 0 2 (0.5)
 Not recorded 0 0 0 1 (4.5) 2 (1.0) 0 3 (0.7)
Median age, years (min–max) 72 (37–98) 52 (33–59) 63 (27–90) 59 (42–76) 54 (21–83) 60 (24–86) 61 (21–98)
Median duration of pain, years (min–max) 1.0 (0.1–73.2) 0.3 (0.2–13.6) 2.6 (0–40.0) 2.2 (0.2–8.1) 2.6 (0.1–50.1) 2.2 (0.1–29.2) 2.1 (0–73.2)
Treatment pathway, n (%)
 Primary 13 (14.6) 1 (20.0) 20 (40.0) 2 (9.1) 35 (17.7) 10 (17.9) 81 (19.3)
 Secondary 48 (53.9) 3 (60.0) 14 (28.0) 13 (59.1) 78 (39.4) 24 (42.9) 180 (42.9)
 Tertiary 28 (31.5) 1 (20.0) 16 (32.0) 7 (31.8) 85 (42.9) 22 (39.3) 159 (37.9)
Baseline ‘average pain’,a n (SD) 7.1 (2.0) 6.4 (1.5) 7.3 (2.0) 7.2 (1.5) 6.8 (1.8) 6.9 (1.8) 6.9 (1.8)
Mean number of concomitant medications,b n (SD) 1.8 (1.5) 1.4 (1.5) 1.5 (1.6) 2.2 (1.4) 1.9 (1.5) 1.7 (1.4) 1.8 (1.5)
  1. aAverage pain during the 7 days prior to screening visit; bNumber of concomitant medications for neuropathic pain at screening visit. CRNP, cancer-related neuropathic pain; FAS, full analysis set; HIV-AN, HIV associated neuropathy; NBP, neuropathic back pain; NPRS, numeric pain rating scale; Other, other non-diabetic PNP; PHN, postherpetic neuralgia; PONP, post-operative and post-traumatic neuropathic pain; SD, standard deviation